

Retraction: *In Vitro* and *In Vivo* Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, and Steven Grant



This article (1) has been retracted at the request of the editors. The AACR Publications Department was notified that the U.S. Department of Health and Human Services' Office of Research Integrity determined that G. Dasmahapatra, the first author of the above-mentioned article, engaged in research misconduct by falsifying and/or fabricating data that appeared in the 2014 article (2). Specifically, respondent reused, and/or relabeled Western blot panels and mouse images and claimed they represented different controls and/or experimental results in: Fig. 3A (JNK 1 and Tubulin), 3B (JNK and Tubulin), and 3C (Tubulin; ref. 2). The matter was reviewed by members of the AACR Publications staff and the MCT editors, who agree that the figure manipulation present in the article merits retraction.

A copy of this Retraction Notice was sent to the last known email addresses for all 6 of the authors. 3 authors (J. Friedberg, S.S. Jones, and S. Grant) agreed to the retraction; 2 authors (H. Patel and S.N. Quayle) did not respond; and 1 author (G. Dasmahapatra) could not be located.

References

1. Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. *In Vitro* and *In Vivo* interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in Non-Hodgkin Lymphoma cells. *Mol Cancer Ther* 2014;13:2886–97.
2. Findings of research misconduct. *Federal Register* 2015;80:76703–4.

Published online June 3, 2019.
Mol Cancer Ther 2019;18:1181
doi: 10.1158/1535-7163.MCT-19-0471
©2019 American Association for Cancer Research.

Molecular Cancer Therapeutics

Retraction: *In Vitro* and *In Vivo* Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, et al.

Mol Cancer Ther 2019;18:1181.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/6/1181>

Cited articles This article cites 2 articles, 1 of which you can access for free at:
<http://mct.aacrjournals.org/content/18/6/1181.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/6/1181>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.